1 / 28

Drug-drug interaction Satellite Workshop

Drug-drug interaction Satellite Workshop. HIV Malaria Co-infection M Lamorde MRCP, PhD. Malaria and HIV. Malaria: major cause of morbidity and mortality in tropics Treatment: artemisinin derivatives are critical for eradication of plasmodium falciparum (responsible for greatest burden)

adamma
Download Presentation

Drug-drug interaction Satellite Workshop

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Drug-drug interaction Satellite Workshop HIV Malaria Co-infection M Lamorde MRCP, PhD

  2. Malaria and HIV • Malaria: major cause of morbidity and mortality in tropics • Treatment: artemisinin derivatives are critical for eradication of plasmodium falciparum (responsible for greatest burden) • Epidemiology: significant geographic overlap with HIV • Complex interactions: pathogenesis, therapeutics • Focus: malaria HIV drug interactions in resource-limited settings

  3. Malaria treatment Uncomplicated malaria artemether/lumefantrine artesunate/amodiaquine Alternative: DHA/piperaquine (previously oral quinine) Severe malaria parenteral quinine parenteralartesunate Uganda: recommended drugs

  4. Antiretroviral therapy First-line (NNRTI-based) efavirenz nevirapine Second-line (PI-based) lopinavir/ritonavir atazanavir/ritonavir Uganda: recommended drugs

  5. Antiretroviral therapy First-line (NNRTI-based) efavirenz nevirapine Second-line (PI-based) lopinavir/ritonavir atazanavir/ritonavir Uganda: recommended drugs CYP3A4 inducers

  6. Antiretroviral therapy First-line (NNRTI-based) efavirenz nevirapine Second-line (PI-based) lopinavir/ritonavir atazanavir/ritonavir Uganda: recommended drugs CYP3A4 inhibitors

  7. Potential for interactions with ARVs

  8. Potential for interactions with ARVs

  9. Malaria treatment Uncomplicated malaria artemether/lumefantrine artesunate/amodiaquine Alternative: DHA/piperaquine (previously oral quinine) Severe malaria parenteral quinine parenteralartesunate Antiretroviral therapy First-line (NNRTI-based) efavirenz nevirapine Second-line (PI-based) lopinavir/ritonavir atazanavir/ritonavir Potential interactions

  10. Case • NGN, F, 43 yrs, HIV diagnosis (2005) • Management • CTX 960 mg OD (since 2005) • AZT/3TC/EFV (since 2008) baseline CD4108 cells/µL • CD4 (2011) 765 cells/µL May 2012 • Loss of appetite, fever, occasional vomiting X 1 week • Self medication with antimalarials (likely artemether/lumefantrine) • No improvement Infectious Diseases Institute, Kampala

  11. Case • NGN, F, 43 yrs, HIV diagnosis (2005) • Management • CTX 960 mg OD (since 2005) • AZT/3TC/EFV (since 2008) baseline CD4108 cells/µL • CD4 (2011) 765 cells/µL May 2012 • Loss of appetite, fever, occasional vomiting X 1 week • Self medication with antimalarials (likely artemether/lumefantrine) • No improvement plasmodium falciparum

  12. Options: AZT/3TC/EFV plus ?

  13. Options: AZT/3TC/EFV plus • EVIDENCE: • No data for efavirenz, some data for nevirapine • PK: In healthy volunteers receiving nevirapine, 33% lower quinine AUC and 36% lower Cmax • Soyinka et al. J PharmPharmacol (2009) • Efficacy: 1 case report of worsening malaria during quinine therapy • Uriel A. Int J STD AIDS (2011)

  14. Options: AZT/3TC/EFV plus ?

  15. Options: AZT/3TC/EFV plus • EVIDENCE: • Safety: First two healthy volunteers in a trial developed significant transaminase elevations with amodiaquine exposure increased 115% & 302%. No artemisinin data. • German P et al. J CID (2007) • Safety: Higher risk of neutropenia among HIV-infected children on antiretroviral therapy • Gasasira AF et al. CID (2008)

  16. Options: AZT/3TC/EFV plus This is what we did ?

  17. Options: AZT/3TC/EFV plus • EVIDENCE: • PK: In 30 Ugandan HIV positive patients without malaria, artemether, DHA, lumefantrine concentrations were reduced by 77%, 75% and 55%,respectively. • Byakika-Kibwika P IAC 2012 TUPE-054 • PK: Similar reductions seen with rifampicin • Lamorde et al 51st ICAAC 2011

  18. Outcome Symptoms resolved with artemether/lumefantrine treatment and patient continues ongoing HIV care at IDI

  19. Issues for discussion • Self-medication with antimalarials and limited capacity for pharmacovigilance in resource-limited settings • Efavirenz and nevirapine lower exposure of critical malaria drugs • Clinical outcomes data needed • ? Potential for resistance

  20. How about malaria treatment for patients receiving protease inhibitors?

  21. Case • AK, M, 52 yrs, city businessman • HIV diagnosis (2004) • Management • CTX 960 mg OD (since 2004) • d4T/3TC/NVP (since 2004) baseline CD477 cells/µL • VL 17,000 copies (2008) • TDF/3TC/LPV/r (since 2008) • Last CD4 (2011) 350 cells/µL June 2012 • Low grade fever (on and off) • Blood film: malaria • Referred to heart institute 2011 • ECG normal • Blood pressure normal • Cholesterol • Total: 230 mg/dL • HDL: 50 mg/dL

  22. Options: Lopinavir/ritonavir plus ?

  23. Options: Lopinavir/ritonavir plus • EVIDENCE: • PK: In healthy volunteers, ritonavir increased the AUC and Cmax of quinine four-fold. • Soyinka et al. Br J ClinPharmacol (2010) • Safety: ? Potential for increased toxicity at standard doses

  24. Options: Lopinavir/ritonavir plus ?

  25. Options: Lopinavir/ritonavir plus • EVIDENCE: • PK: Ugandan HIV+ patients without malaria (n = 32), lumefantrineconcentrations increased by 386% while artemether decreased by 43% • Byakika-Kibwika P, J AntimicrobChemother (2012) • PK: Lumefantrine markedly higher in SA patients on LPV/r • T Kredo,CROI 2012 (Paper # 613) • Efficacy: Randomized trial in Ugandan HIV+ children (n=176): 43% lower risk of malaria recurrence in lopinavir/ritonavir arm versus NNRTI arm. • Achan J, CROI 2012 (Paper #26)

  26. Safety?

  27. Options: Lopinavir/ritonavir plus • EVIDENCE: • Safety: Structurally similar to halofantrine which causes QT prolongation • Single dose studies: No QTc prolongation in healthy volunteers or Ugandan patients • German P, JAIDS 2009; Byakika-Kibwika P, Chem Res and Pract, 2011 • However, lumefantrine accumulates with repeated dosing and no safety data with six-dose regimen

  28. Acknowledgements www.hiv-druginteractionslite.org • Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala • Ivan Mambule • Jane Achan • Pauline Byakika-Kibwika

More Related